Bridging EGFR/TGF-β Signaling to Bypass Resistance to Immune Checkpoint Blockade.

Although EGFR is a common target in squamous cancers, anti-EGFR monotherapies have shown modest success because of existing or acquired activation of other oncogenic pathways and tumor heterogeneity. A bifunctional fusion protein ficerafusp alfa in combination with pembrolizumab represents a potential solution to overcome resistance in early-phase clinical investigation. See related article by Hernando-Calvo et al., p. 4623.